Moving an advanced therapy from scientific discovery to a GMP-manufactured product is one of the greatest challenges in cell and gene therapy development. This panel will explore how organisations can overcome scientific, manufacturing and regulatory barriers to deliver robust, scalable and commercially viable therapies. Experts will discuss the importance of early manufacturing strategy, process development, quality, analytics and regulatory planning in accelerating successful translation.
- When should manufacturing and CMC strategy become part of therapy development, and what are the risks of leaving it too late?
- What are the biggest challenges in translating a promising laboratory process into a robust, scalable GMP manufacturing process without compromising product quality or potency?
- How can developers balance quality, regulatory expectations and cost while preparing advanced therapies for clinical and commercial manufacture?
- Looking ahead, which innovations will have the greatest impact on accelerating the development and manufacture of advanced therapies?